LENSAR, Inc. LNSR · NASDAQ
$5.80 -3.81% (-$0.23)
Summary
69 / 100 · Bulios Score
What speaks for it
- Out of every 100 USD of revenue, 58 USD is left as net profit.
- Revenue grew by 18% a year over the last 3 years.
- It holds more cash than debt: $13.6M against $2.38M.
- You pay 2.1 USD for 1 USD of yearly profit, little for its sector.
What to watch
- It reports a profit, yet spends more cash than it brings in.
- It missed profit estimates 5 times in the last 8 quarters.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapToday you pay 2.1 USD for 1 USD of yearly profit.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 17% a year over 5 years. Over the last 3 years it grew by 18% a year.
Growth in detailDoes it make money?
ReasonablyWhere 100 USD of revenue goes
- Cost of sales 52 USD
- Research and development 8.8 USD
- Sales and administration 53 USD
- Taxes and other -71 USD
- Net profit 58 USD
Net profit, industry median (Medical - Devices) 7.0 USD
Out of every 100 USD of revenue, 58 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesOver the last 12 months it spent more cash than it brought in. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 2
- Hold 1
- Sell 0
Today's price within the analysts' price targets
The average target of $12 is 107% above today's price. 67% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Product 89%
- Service 11%
By region
- UNITED STATES 66%
- Europe 16%
- Asia Excluding South Korea 16%
- KOREA, REPUBLIC OF 1.3%
- Other Geographical Region 0.5%
Product brings in 89% of revenue. Service grew fastest, by 15% a year.
Segments in detail